A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

NCT ID: NCT06614179

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Secondary objective: To establish a grading model of abdominal tumors based on clinical indicators Exploratory Objective: To include CT scans in large-scale non-tumor populations for validation and to improve model accuracy Certainty

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with abdominal tumors:
* all patients were pathologically diagnosed with abdominal tumors;
* The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
* All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
* Non-tumor population:
* all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.

Exclusion Criteria

* Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xiangdong Cheng

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiangdong Cheng

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiangdong Cheng

Role: PRINCIPAL_INVESTIGATOR

Zhejiang Cancer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)

Hangzhou, Zhejiang, China

Site Status RECRUITING

Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiangdong Cheng

Role: CONTACT

0086-571-881280

Can Hu

Role: CONTACT

13968032995

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiangdong Cheng, PhD.

Role: primary

+0086-0571-88128041

Pengfei Yu, MD,PhD

Role: primary

+86-571-88128031

References

Explore related publications, articles, or registry entries linked to this study.

Hu C, Xia Y, Zheng Z, Cao M, Zheng G, Chen S, Sun J, Chen W, Zheng Q, Pan S, Zhang Y, Chen J, Yu P, Xu J, Xu J, Qiu Z, Lin T, Yun B, Yao J, Guo W, Gao C, Kong X, Chen K, Wen Z, Zhu G, Qiao J, Pan Y, Li H, Gong X, Ye Z, Ao W, Zhang L, Yan X, Tong Y, Yang X, Zheng X, Fan S, Cao J, Yan C, Xie K, Zhang S, Wang Y, Zheng L, Wu Y, Ge Z, Tian X, Zhang X, Wang Y, Zhang R, Wei Y, Zhu W, Zhang J, Qiu H, Su M, Shi L, Xu Z, Zhang L, Cheng X. AI-based large-scale screening of gastric cancer from noncontrast CT imaging. Nat Med. 2025 Sep;31(9):3011-3019. doi: 10.1038/s41591-025-03785-6. Epub 2025 Jun 24.

Reference Type DERIVED
PMID: 40555751 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IIT-2024-279

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.